Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk c19early.org/fm Wagner et al. Famotidine for COVID-19 LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? Retrospective 1,457 patients in the USA (March 2020 - March 2021) Lower mortality with famotidine (p<0.000001) Wagner et al., American J. Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec Favors famotidine Favors control
Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A Retrospective Study
Wagner et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec
Wagner et al., Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A.., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
risk of death, 70.0% lower, OR 0.30, p < 0.001, treatment 638, control 819, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wagner et al., 31 Oct 2021, retrospective, USA, peer-reviewed, 5 authors, study period March 2020 - March 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Gastrointestinal Symptoms and Association With Respiratory Symptoms in Patients Diagnosed With SARS-CoV 2 (COVID-19)
MD Ernesto Robalino Gonzaga, MD Irene Riestra Guiance, MD Richard Henriquez, MD Mahmoud Ibrahim, MD Yuya Nway, DO Minh Ho, Jane Ha, MD, PhD Yeongkeun Kwon, BS Dohyang Kim, PhD Jinseub Hwang, PhD Jin-Won Kwon, MD, PhD Sungsoo Park
Figure 1. Panel a: Hospitalized COVID-19 patients with GI Symptoms on Admission demographic characteristics and ICU or non ICU admissions comparing with presence or no of respiratory symptoms. Panel b: Odds Ratio Estimates for ICU Admission in Patients with COVID-19 presenting with GI symptoms.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit